ACE NanoMed Secures Matching Fund from RAISe+; Invites Strategic Investors to Propel Novel Drug from Lab to Clinic

ACE NanoMed (the "Company"), a pioneering biotechnology firm focused on nanomedicine innovation, announced it has been awarded a matching fund under the Research, Academic and Industry Sectors One-plus (RAISe+) Scheme of the Hong Kong government. This significant funding will accelerate the translation of its lead innovative drug candidate from research into clinical trial.

The RAISe+ Scheme, launched in October 2023 with a total allocation of HKD 10 billion, operates on a matching basis to support research teams with strong commercialisation potential from eight universities under the University Grants Committee. Each project can receive up to HKD 100 million across two phases—Phase I focusing on R&D translation (with a government-to-university matching ratio of 2:1) and Phase II on commercialisation (1:1 ratio).  The Company is proud to be one of three projects from The Chinese University of Hong Kong (CUHK) awarded in this batch.

Beyond the RAISe+ funding, ACE NanoMed has secured robust financial commitment from a major pharmaceutical company in Mainland China and a leading venture capital firm in Hong Kong. This powerful syndicate provides not only capital but also deep industry expertise, manufacturing capabilities, and commercial pathways—critical assets as the company transitions from research to regulatory approval and market entry.

“The RAISe+ matching fund is a game-changer. It validates our science and de-risks our early development,” said Professor K.W. Lo, of ACE NanoMed. “Coupled with the unwavering support of our strategic pharma partner and a Hong Kong venture capital, we are now fully confident in advancing our novel drug into clinical trials. We extend our deepest gratitude to the Hong Kong SAR Government, The Chinese University of Hong Kong, Hong Kong Science and Technology Parks, our strategic partners, investors, advisors, and everyone who has guided us to this success over the past years.”

Open for Further Investment to Scale to the Next Level

While the current funding enables the leap to clinical trial, ACE NanoMed is actively seeking additional investment from the market to accelerate its growth trajectory. The Company is now opening a new funding round to bring on board like-minded institutional and strategic investors.

“RAISe+ provides powerful leverage and government endorsement, but to truly bring our drug to patients faster and scale our platform to the next level, we need additional partners,” added Professor Anna Tsang. “We are open to further support from the investors who share our vision of transforming nanomedicine.”

About ACE NanoMed

ACE NanoMed is a biotechnology company based in Hong Kong, spun off from The Chinese University of Hong Kong. The company focuses on developing innovative nanomedicines to address unmet medical needs. Leveraging cutting-edge research, ACE NanoMed aims to advance a pipeline of novel therapeutics from discovery through clinical development.

About RAISe+

Launched in October 2023 and backed by a HKD 10 billion government allocation, RAISe+ (Research, Academic and Industry Sectors One-plus Scheme) provides matching funds to university research teams with strong commercial potential.